Merck Ups The Calibr Of Academic-Industry Cooperation
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck announced March 15 that it plans to invest $90 million over the next seven years in a nonprofit biomedical research center in San Diego dubbed the California Institute for Biomedical Research, or Calibr.
You may also be interested in...
Surge In Partnerships And Licensing In China Highlights Need For Greater Flexibility
As cross-border deals rise rapidly and finding new partners becomes harder in China, multinational drug makers must be flexible in their deal strategies. Seasoned executives from AstraZeneca, Bayer, Merck and Chinese startup Ascletis offer insights on what to look for in a dynamic market.
Surge In Partnerships And Licensing In China Highlights Need For Greater Flexibility
As cross-border deals rise rapidly and finding new partners becomes harder in China, multinational drug makers must be flexible in their deal strategies. Seasoned executives from AstraZeneca, Bayer, Merck and Chinese startup Ascletis offer insights on what to look for in a dynamic market.
Sanofi And Joslin Team Up On Diabetes Discovery
Sanofi continues to look for new, innovative ways to diversify its diabetes portfolio; its latest endeavor is a discovery collaboration with Harvard Medical School’s Joslin Diabetes Center.